시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 절제 불가능 간세포암 시장 보고서(2025년)
Unresectable Hepatocellular Carcinoma Global Market Report 2025
상품코드 : 1824467
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

절제 불가능 간세포암 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.9%로 성장할 전망이며, 29억 3,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 헬스케어 정책의 변화, 환자 계층화 전략, 실제 임상 증거 활용, 환자 광고 및 인지도, 경제 및 역학에 기인할 것으로 예측됩니다. 예측 기간 주요 동향으로는 정밀의료 및 바이오 마커, 실제 세계 증거 및 데이터 통합, 집학적 접근, 세계 임상시험 및 공동 연구, 환자 중심 치료 등이 있습니다.

향후 5년간의 성장률 9.9%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 무역 마찰은 캐나다와 호주에서 개발된 이트륨-90 미세구의 가격을 상승시키고, 인터벤셔널 종양학적 치료의 지연과 종양학적 비용의 상승을 초래함으로써, 표적 방사성 색전 요법의 미국에서의 채용을 방해할 수 있습니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.

간암의 유병률 상승이 절제 불가능 간세포암 시장의 향후 성장을 뒷받침하고 있습니다. 간암은 건강한 간세포가 종양 세포로 추월되어 통제 불능으로 증식하기 시작하여 발생합니다. 절제 불가능 간세포암은 간 이식과 라디오파 소작술에 의해 치료되는 암의 일종입니다. 예를 들어, 2022년 10월, 스위스에 본부를 둔 사독 과학 잡지 'Journal of Hepatology'는 2020년에 전 세계 830,200명이 간암으로 사망하였고, 2020-2040년에 새롭게 140만 명의 간암 환자가 발생할 것으로 예측되며, 이는 매년 55.0%의 신규 환자 증가를 반영하고 있다고 보고하고 있습니다. 게다가 미국의 비영리단체인 미국암협회는 2024년 1월 미국에서 원발성 간암과 간내 담관암이 새로 약 41,630명(남성 28,000명, 여성 13,630명) 진단받아 약 29,840명(남성 19,120명, 여성 10,72명)이 사망한 것으로 평가했습니다. 따라서 간암의 유병률 증가가 절제 불가능 간세포암 시장의 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Unresectable hepatocellular carcinoma refers to an aggressive tumor that commonly develops in conjunction with cirrhosis and chronic liver disease. Treatment options for unresectable hepatocellular carcinoma include surgical resection, liver transplant, ablation, and embolization.

The main types of unresectable hepatocellular carcinoma are primary, secondary, and benign liver growth. In this context, 'primary' signifies a greater significance, and as the most prevalent form of primary liver cancer, hepatocellular carcinoma is particularly noteworthy. Various treatment approaches, such as chemotherapy, molecularly targeted therapy, immunotherapy, and others, are employed in hospitals, specialty clinics, and cancer centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The unresectable hepatocellular carcinoma market research report is one of a series of new reports from The Business Research Company that provides unresectable hepatocellular carcinoma market statistics, including unresectable hepatocellular carcinoma industry global market size, regional shares, competitors with a unresectable hepatocellular carcinoma market share, detailed unresectable hepatocellular carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the unresectable hepatocellular carcinoma industry. This unresectable hepatocellular carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The unresectable hepatocellular carcinoma market size has grown marginally in recent years. It will grow from $1.98 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 1.5%. The growth in the historic period can be attributed to chemotherapy advances, clinical trial outcomes, liver transplantation limitations, increased cancer cases, expanded access to therapies.

The unresectable hepatocellular carcinoma market size is expected to see strong growth in the next few years. It will grow to $2.93 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to healthcare policy changes, patient stratification strategies, real-world evidence utilization, patient advocacy and awareness, economic and dynamics. Major trends in the forecast period include precision medicine and biomarkers, real-world evidence and data integration, multidisciplinary approaches, global clinical trials and collaborations, and patient-centric care.

The forecast of 9.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of targeted radioembolization therapies by inflating prices of yttrium-90 microspheres developed in Canada and Australia, resulting in delayed interventional oncology procedures and higher oncology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of liver cancer is propelling the growth of the unresectable hepatocellular carcinoma market moving forward. Liver cancer occurs when healthy liver cells are overtaken by tumor cells that begin to grow uncontrollably. Unresectable hepatocellular carcinoma is a form of cancer that is treated through liver transplantation and radiofrequency ablation. For example, in October 2022, the Journal of Hepatology, a peer-reviewed scientific journal based in Switzerland, reported that globally, 830,200 individuals died from liver cancer in 2020, with an anticipated 1.4 million new liver cancer cases expected between 2020 and 2040, reflecting a 55.0% increase in new cases annually. Additionally, in January 2024, the American Cancer Society, a US-based non-profit organization, projected that around 41,630 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed in the U.S. in 2024 (28,000 in men and 13,630 in women), with approximately 29,840 deaths expected (19,120 men and 10,720 women). Therefore, the increasing prevalence of liver cancer is driving the growth of the unresectable hepatocellular carcinoma market.

The growth in healthcare expenditure is anticipated to drive the unresectable hepatocellular carcinoma market forward. Healthcare expenditure encompasses the total financial resources allocated to activities aimed at promoting, restoring, and maintaining health. As unresectable hepatocellular carcinoma progresses and becomes more complex, treatment options tend to become costlier. For example, in 2021, health spending experienced an average increase of approximately 6%, while a report by JPMorgan Chase & Co. in May 2022 revealed an overall 23% surge in healthcare spending in the same year. The growing healthcare expenditure is expected to be a significant driver in the expansion of the unresectable hepatocellular carcinoma market.

The increasing consumption of beer is anticipated to drive the growth of the unresectable hepatocellular carcinoma market moving forward. Beer consumption refers to the act of drinking beverages that contain ethyl alcohol, specifically beer. Excessive alcohol intake, including beer, is a well-recognized risk factor for developing hepatocellular carcinoma (HCC). Chronic alcohol use can harm liver cells, resulting in inflammation, fibrosis, and eventually cirrhosis, creating a conducive environment for HCC development. For instance, in December 2023, data published by Kirin Holdings Co. Ltd., a Japan-based company specializing in alcoholic and non-alcoholic beverages and pharmaceuticals, revealed that global beer consumption increased by approximately 5.4 million kiloliters in 2022, equivalent to about 8.5 billion bottles (633 ml each) compared to the previous year. Therefore, the rising beer consumption is contributing to the growth of the unresectable hepatocellular carcinoma market.

Innovations in products emerge as a notable trend gaining traction in the unresectable hepatocellular carcinoma market. Major companies operating in this market are actively pursuing the development of innovative products to maintain their market positions. For instance, AstraZeneca, a pharmaceutical and biotechnology company based in the UK, introduced Imjudo (tremelimumab) in combination with Imfinzi for unresectable liver cancer. This treatment, known as the STRIDE regimen, involves a single dose of anti-CTLA-4 antibody Imjudo 300mg combined with anti-PD-L1 antibody Imfinzi 1500 mg every four weeks. Patients receiving this combination showed a 22% lower chance of mortality compared to those receiving sorafenib.

Major players in the unresectable hepatocellular carcinoma market are focusing on the development of combination therapies to address the complexities of this condition. For example, Ono Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, launched Opdivo (nivolumab) Intravenous Infusion in combination with Yervoy in March 2023. Opdivo, a human anti-human PD-1 monoclonal antibody, works by blocking the interaction between PD-1 on T cells and its ligands on cancer cells, thereby enhancing T cells' ability to recognize and eliminate cancer cells more effectively. This development reflects the commitment of major companies to provide effective therapeutic options for unresectable hepatocellular carcinoma conditions.

Major companies operating in the unresectable hepatocellular carcinoma market include Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, Astrazeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, Mendus AB.

North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the unresectable hepatocellular carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The unresectable hepatocellular carcinoma market includes revenues earned by entities by providing first-line agents, surgical resection, and liver transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Unresectable Hepatocellular Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on unresectable hepatocellular carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for unresectable hepatocellular carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The unresectable hepatocellular carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Unresectable Hepatocellular Carcinoma Market Characteristics

3. Unresectable Hepatocellular Carcinoma Market Trends And Strategies

4. Unresectable Hepatocellular Carcinoma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Unresectable Hepatocellular Carcinoma Growth Analysis And Strategic Analysis Framework

6. Unresectable Hepatocellular Carcinoma Market Segmentation

7. Unresectable Hepatocellular Carcinoma Market Regional And Country Analysis

8. Asia-Pacific Unresectable Hepatocellular Carcinoma Market

9. China Unresectable Hepatocellular Carcinoma Market

10. India Unresectable Hepatocellular Carcinoma Market

11. Japan Unresectable Hepatocellular Carcinoma Market

12. Australia Unresectable Hepatocellular Carcinoma Market

13. Indonesia Unresectable Hepatocellular Carcinoma Market

14. South Korea Unresectable Hepatocellular Carcinoma Market

15. Western Europe Unresectable Hepatocellular Carcinoma Market

16. UK Unresectable Hepatocellular Carcinoma Market

17. Germany Unresectable Hepatocellular Carcinoma Market

18. France Unresectable Hepatocellular Carcinoma Market

19. Italy Unresectable Hepatocellular Carcinoma Market

20. Spain Unresectable Hepatocellular Carcinoma Market

21. Eastern Europe Unresectable Hepatocellular Carcinoma Market

22. Russia Unresectable Hepatocellular Carcinoma Market

23. North America Unresectable Hepatocellular Carcinoma Market

24. USA Unresectable Hepatocellular Carcinoma Market

25. Canada Unresectable Hepatocellular Carcinoma Market

26. South America Unresectable Hepatocellular Carcinoma Market

27. Brazil Unresectable Hepatocellular Carcinoma Market

28. Middle East Unresectable Hepatocellular Carcinoma Market

29. Africa Unresectable Hepatocellular Carcinoma Market

30. Unresectable Hepatocellular Carcinoma Market Competitive Landscape And Company Profiles

31. Unresectable Hepatocellular Carcinoma Market Other Major And Innovative Companies

32. Global Unresectable Hepatocellular Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Unresectable Hepatocellular Carcinoma Market

34. Recent Developments In The Unresectable Hepatocellular Carcinoma Market

35. Unresectable Hepatocellular Carcinoma Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기